January 2019
Earle A. Chiles Research Institute, a division of Providence Cancer Institute in the Robert W. Franz Cancer Center, is currently conducting more than 120 research studies, including clinical trials of targeted therapies and novel immunotherapy approaches.
Melanoma study: are two immunotherapies better than one?
A newly opened Phase 3 study at Providence Cancer Institute will compare the benefits of two immunotherapies, nivolumab and NKTR-214 , against nivolumab alone for patients with advanced melanoma. Nivolumab (Opdivo), an FDA-approved treatment, has already been shown to offer a survival benefit for metastatic melanoma. Early research into combining nivolumab with the investigational immunotherapy NKTR-214 have revealed promising antitumor activity.
All current open studies:
Find additional studies for many types of cancer in Multiple Tumor Types .
New studies are posted frequently - please check our  website  for a complete list of our current studies. For more information, call 503-215-2614.